Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 May 18];8(6):s450. Available from: https://skin.dermsquared.com/skin/article/view/3052